Neurosense Therapeutics Stock Market Value
| NRSN Stock | USD 0.90 0.02 2.17% |
| Symbol | Neurosense |
Neurosense Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurosense Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurosense Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurosense Therapeutics.
| 12/06/2022 |
| 11/25/2024 |
If you would invest 0.00 in Neurosense Therapeutics on December 6, 2022 and sell it all today you would earn a total of 0.00 from holding Neurosense Therapeutics or generate 0.0% return on investment in Neurosense Therapeutics over 720 days. Neurosense Therapeutics is related to or competes with Quoin Pharmaceuticals, Revelation Biosciences, Neurobo Pharmaceuticals, Virax Biolabs, Nutriband, Longeveron LLC, and RenovoRx. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments f... More
Neurosense Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurosense Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurosense Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.87 | |||
| Information Ratio | 0.0244 | |||
| Maximum Drawdown | 30.01 | |||
| Value At Risk | (7.38) | |||
| Potential Upside | 10.11 |
Neurosense Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurosense Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurosense Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neurosense Therapeutics historical prices to predict the future Neurosense Therapeutics' volatility.| Risk Adjusted Performance | 0.0459 | |||
| Jensen Alpha | 0.088 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.0271 | |||
| Treynor Ratio | 0.1854 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics Backtested Returns
Neurosense Therapeutics appears to be very risky, given 3 months investment horizon. Neurosense Therapeutics has Sharpe Ratio of 0.0828, which conveys that the firm had a 0.0828% return per unit of risk over the last 3 months. We have found thirty technical indicators for Neurosense Therapeutics, which you can use to evaluate the volatility of the firm. Please exercise Neurosense Therapeutics' Mean Deviation of 3.78, downside deviation of 4.87, and Risk Adjusted Performance of 0.0459 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neurosense Therapeutics holds a performance score of 6. The company secures a Beta (Market Risk) of 1.36, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurosense Therapeutics will likely underperform. Please check Neurosense Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Neurosense Therapeutics' current price movements will revert.
Auto-correlation | 0.30 |
Below average predictability
Neurosense Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Neurosense Therapeutics time series from 6th of December 2022 to 1st of December 2023 and 1st of December 2023 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurosense Therapeutics price movement. The serial correlation of 0.3 indicates that nearly 30.0% of current Neurosense Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.3 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Neurosense Therapeutics lagged returns against current returns
Autocorrelation, which is Neurosense Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neurosense Therapeutics' stock expected returns. We can calculate the autocorrelation of Neurosense Therapeutics returns to help us make a trade decision. For example, suppose you find that Neurosense Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Neurosense Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neurosense Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neurosense Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neurosense Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Neurosense Therapeutics Lagged Returns
When evaluating Neurosense Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neurosense Therapeutics stock have on its future price. Neurosense Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neurosense Therapeutics autocorrelation shows the relationship between Neurosense Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Neurosense Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neurosense Stock
| 0.62 | BACK | IMAC Holdings | PairCorr |
| 0.47 | VALN | Valneva SE ADR | PairCorr |
| 0.37 | AGL | agilon health | PairCorr |
| 0.36 | IPSC | Century Therapeutics | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Correlation, Neurosense Therapeutics Volatility and Neurosense Therapeutics Alpha and Beta module to complement your research on Neurosense Therapeutics. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.